Lonza signs exclusive agreement with Index Ventures

Five year agreement includes all companies where Index Ventures will be the majority shareholder

13-Jan-2014 - Switzerland

Lonza and Index Ventures, LLP announced an exclusive agreement for process development and cGMP production for all biological products in the portfolio of companies where Index is the major investor.

Over the course of the agreement, additional development and manufacturing projects will be added to the product list, as future investments are made by Index.

“This agreement shows that Lonza’s value to a company’s product development pipeline is being recognized more widely by investors in biotech companies,” said Dr. Stephan Kutzer, COO Lonza Pharma&Biotech. “This multi-product agreement demonstrates Lonza’s ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle.” 

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics